Eli Lilly Prevents Drugs to Stop Coronavirus Infection in Nursing Homes

The pharmaceutical company Eli Lilly on Thursday conducted an unusual experiment to protect nursing home staff members and residents from infection with coronavirus.

A drug containing monoclonal antibodies – laboratory-developed virus-fighters – prevented symptomatic infections in residents exposed to the virus, even those of the frail age who are most vulnerable, in partnership with national institutions. According to the preliminary results of the study. Health.

Eli Lilly said researchers found an 80 percent reduction in infections among drug-seeking residents, compared with those receiving a placebo, and a 60 percent reduction among employees, with results that were highly statistically powerful, Eli Lilly said.

The data has not yet been peer-reviewed or published. The company hopes to present the findings at a future medical meeting and publish them in a peer-reviewed journal, but did not say when.

The study included 965 participants in nursing homes: 666 staff members and 299 residents. (The company expected more residents to participate, but it proved difficult to enroll them; many had dementia, and others were lairs to receive an intravenous drug.)

Four deaths occurred from Kovid-19 in study participants. All were from nursing home residents who received a placebo, not medicine.

The drug, bamalanivimab, already has an emergency use authority from the Food and Drug Administration that allows Eli Lilly to provide it to patients early in the course of their infection.

But this study asked if the drug could prevent infection before it started. this Was an unusual experiment: In trucks equipped with mobile labs, medical staff go to the nursing home, there was only one infection. As soon as the activists arrived, they set up temporary infusion centers to conduct the drug.

The research coincided with an emergency meeting of the Data Protection and Monitoring Board later this week, an independent group monitoring the results to come. The data were robust and sufficiently convincing to prevent placebo.

Kovid 19 Vaccines>

Answers to your vaccine questions

However, the exact order of those receiving the vaccine may vary by state, but the first will likely be medical workers and residents of long-term care facilities. If you want to understand how this decision is being made, This article will help.

Life will be normal only when society has adequate protection against coronovirus. Once countries authorize a vaccine, they will only be able to get some percent of their citizens vaccinated in the first two months. The unaffiliated majority will still be vulnerable to infection. Stronger protection against sickness from the growing vaccines of coronaviruses has been shown. But it is also possible for people to spread the virus without being infected because they only experience mild symptoms or none at all. Scientists do not yet know whether vaccines inhibit the transmission of coronovirus. So for the time being, even those vaccinated will have to wear masks, avoid indoor congestion, and so on. Once enough people are vaccinated, it will be very difficult for coronoviruses to infect those unprotected. Depending on how soon we as a society achieve that goal, by 2021, life can come as normal.

Yes, but not forever. The two vaccines likely to be authorized this month will clearly protect people from Kovid-19 from getting sick. But the clinical trials that gave these tests were not designed to determine whether those vaccinated could still spread coronaviruses without developing symptoms. This remains a possibility. We know that people who are naturally infected with coronovirus can spread it when they are not experiencing any cough or other symptoms. Researchers will study this question in depth as the vaccine rolls out. Meanwhile, even vaccinated people will need to think of themselves as potential broadcasters.

The Pfizer and BioNTech vaccines are given as a shot in the arm, like other specialized vaccines. The injection will not be different from those you have received before. Thousands of people have already received vaccines, and none of them have reported serious health problems. But some of them have experienced short-term discomfort, including pain and flu-like symptoms that usually last a day. It is possible that people may need to plan to leave work or school one day after the second shot. While these experiences are not pleasant, they are a good sign: they are the result of your own immune system experiencing the vaccine and exacerbating a powerful response that will provide long-lasting immunity.

No. Modernism and Pfizer vaccines use a genetic molecule to prime the immune system. The molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oily bubble that can fuse a cell, allowing the molecule to slip. The cell uses mRNA to make proteins from the coronovirus, which can stimulate the immune system. At any given moment, each of our cells may contain hundreds of thousands of mRNA molecules, which they produce to make their own proteins. Once they become proteins, our cells cut mRNA with special enzymes. The mRNA molecules that make up our cells can only survive for a few minutes. The mRNA in the vaccine is engineered to withstand the cell’s enzymes for a short time, so that cells can make additional virus proteins and indicate a strong immune response. But mRNA can only remain for a few days before it is destroyed.

“My jaw dropped, when I saw the table of results,” said Dr. Professor of Medicine at the University of North Carolina at Chapel Hill and a principal investigator who helped design and implement the study. Myron Cohen said.

Although the study has ended, Eli Lilly’s chief scientist, Dr. Daniel Skowronski said the company would continue to participate in nursing homes in its study network when its outbreak is detected. “Everyone will get medicine,” he said.

Experts who were not part of the study were enthusiastic, but insisted that they had not yet seen the complete data. Dr., director of the Exact Vaccine Program at Boston Children’s Hospital. Ofer Levy said, “I’m only seeing positivity here.” “It’s a win.”

Director of the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine, Dr. Kathleen Newsill was also encouraged.

“The mortality effect is notable,” he said, adding that the drug should be used more widely to prevent and treat Kovid-19, especially in populations such as nursing home residents who have high mortality rates and Sub-properties may be the response for vaccines. “

Vaccines also, of course, protect people from infection with the virus, and nursing home staff and residents were among the first group to have a preference for shots. But supplies are insufficient, and many nursing home workers, fearful of vaccines, have refused to receive them.

And after vaccination, it can take six weeks for the body to produce enough antibodies for maximum protection, Drs. Said Srilatha Edupuganti, a vaccine researcher and a study investigator at Emory University in Atlanta.

Monoclonal antibody treatment, she said, can give almost the same protection immediately, although it will not last as long as the protection given by the vaccine.

Eli Lilly plans to contact the FDA regarding an emergency use authority for drug use to prevent infection in older populations, especially in nursing homes or long-term care facilities, Drs. Skovrowski said.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *